MedTrace Logo

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

NCT04846478 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-05-12

No results posted yet for this study

Summary

This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer.

The names of the study drugs involved in this study are:

* Talazoparib
* Tazemetostat

Conditions

Interventions

DRUG

Talazoparib

capsule, taken by mouth, once a day

DRUG

Tazemetostat

orally as a tablet twice daily.

Sponsors & Collaborators

Principal Investigators

  • Atish Choudhury, MD PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-28
Primary Completion
2025-09-25
Completion
2026-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04846478 on ClinicalTrials.gov